Caelus is a biotech company developing microbial therapies for metabolic disorders, among others. The most advanced program focuses on the bacterial strain Anaerobutyricum soehngenii (AS) and has shown promising results in clinical trials regarding the prevention and treatment of type 2 diabetes.